S&P Futures
4,571.50 +13.50 (+0.30%) Dow Futures
35,677.00 +57.00 (+0.16%) Nasdaq Futures
15,585.25 +89.50 (+0.58%) Russell 2000 Futures
2,314.40 +4.10 (+0.18%) Crude Oil
83.34 -0.42 (-0.50%) Gold
1,802.60 -4.20 (-0.23%)
Merck & Co., Inc. (MRK)
Chart Events
Performance Outlook
| Previous Close | 81.15 |
| Open | 81.03 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1200 |
| Day's Range | 79.95 - 81.72 |
| 52 Week Range | 68.44 - 84.56 |
| Volume | 8,937,981 |
| Avg. Volume | 13,453,856 |
| Market Cap | 206.712B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 37.19 |
| EPS (TTM) | 2.20 |
| Earnings Date | Oct 28, 2021 |
| Forward Dividend & Yield | 2.60 (3.20%) |
| Ex-Dividend Date | Sep 14, 2021 |
| 1y Target Est | 93.88 |
Fair Value
Related Research
- Merck & Company, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.RatingFair ValueEconomic Moat11 days agoMorningstar
- Zacks
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
- Reuters
Indonesia in talks to buy Merck's COVID-19 antiviral pill - minister
Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday. Results https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 from a large clinical trial this month showed that the pill, made with Ridgeback Biotherapeutics, cut hospitalisations and deaths by 50%. Merck asked for an emergency use clearance from the United States earlier this month.
- Business Wire
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
KENILWORTH, N.J., October 25, 2021--Merck Announces Positive Top-Line Results from Phase 3 Trials for Once-Daily Oral Combination of Doravirine/Islatravir for Treatment HIV-1 Infection
- Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia AreataBusiness Wire
- TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid TumorsGlobeNewswire
